PTEN and prostate carcinoma: Mechanistically, LUBAC (HOIP+SHARPIN) conjugates Met1-Ub chains to PTEN, which significantly inhibits PTEN phosphatase activity and accelerates the activation of PI3K/AKT signaling, promoting prostate cancer progression (Guo et al.2022).